Inactivation of cytochrome P-450 by the drug methoxsalen

H Fouin-Fortunet, M Tinel, V Descatoire, P Letteron, D Larrey, J Geneve and D Pessayre

Administration of methoxsalen (50 mumol X kg-1 i.p.) increased 4-fold the hexobarbital sleeping time in rats; at this low dose, SKF 525-A, piperonyl butoxide and cimetidine had little or no effect. In vitro, the concentration of methoxsalen inhibiting by 50% monooxygenase activities ranged from 10 microM (for benzo(a)-pyrene and hexobarbital hydroxylases] to 25 microM for 7-ethoxy-coumarin deethylase and aminopyrine demethylase); these values were in the range of those observed with SKF 525-A (1-50 microM) or piperonyl butoxide (10-100 microM) but much lower than those for cimetidine (100-500 microM). Methoxsalen (25-1000 microM) decreased cytochrome P-450 in vitro, in the presence of EDTA; this effect required NADPH and oxygen, was decreased by piperonyl butoxide and was increased by phenobarbital pretreatment. Similarly, administration of methoxsalen (125 mumol X kg- 1 i.p.) decreased cytochrome P-450 and monooxygenase activities in vivo; the decrease in cytochrome P-450 was enhanced by phenobarbital pretreatment and was prevented by piperonyl butoxide. There was no evidence for lipid peroxidation, denaturation into cytochrome P-420, formation of cytochrome P-450-metabolite complexes, destruction of heme or formation of green pigments. In contrast, a reactive metabolite of methoxsalen covalently bound to microsomal proteins; covalent binding required NADPH and oxygen, was decreased by piperonyl butoxide and was increased by phenobarbital pretreatment. We conclude that methoxsalen is activated into a metabolite which destroys cytochrome P-450.

Volume 236, Issue 1, pp. 237-247, 01/01/1986
Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. Rheeders, M. Bouwer, and T. C. Goosen Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine. J. Clin. Pharmacol., July 1, 2006; 46(7): 768 - 775. [Abstract] [Full Text] [PDF]

				H. E. Kleiner, S. V. Vulimiri, L. Miller, W. H. Johnson Jr, C. P. Whitman, and J. DiGiovanni Oral administration of naturally occurring coumarins leads to altered phase I and II enzyme activities and reduced DNA adduct formation by polycyclic aromatic hydrocarbons in various tissues of SENCAR mice Carcinogenesis, January 1, 2001; 22(1): 73 - 82. [Abstract] [Full Text] [PDF]

				B. D. SCHULTZ, A. K. SINGH, D. C. DEVOR, and R. J. BRIDGES Pharmacology of CFTR Chloride Channel Activity Physiol Rev, January 1, 1999; 79(1): 109 - 144. [Abstract] [Full Text] [PDF]

				L. L. Koenigs, R. M. Peter, S. J. Thompson, A. E. Rettie, and W. F. Trager Mechanism-Based Inactivation of Human Liver Cytochrome P450 2A6 by 8-Methoxypsoralen Drug Metab. Dispos., December 1, 1997; 25(12): 1407 - 1415. [Abstract] [Full Text]